Lv1
18 积分 2024-08-25 加入
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study
6个月前
已完结
Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma
6个月前
已完结
Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance
6个月前
已完结
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
6个月前
已完结
[The guideline of the diagnosis and treatment of mantle cell lymphoma in China (2022)]
6个月前
已完结
[Chinese expert consensus on the diagnosis and management of elderly patients with diffuse large B-cell lymphoma (2024)]
7个月前
已完结
Therapeutic progress in relapsed/refractory multiple myeloma
9个月前
已完结
皖公网安备34019202002308
